company background image
SRRK

Scholar Rock Holding NasdaqGS:SRRK Stock Report

Last Price

US$12.23

Market Cap

US$631.8m

7D

-2.3%

1Y

-29.1%

Updated

02 Feb, 2023

Data

Company Financials +

Scholar Rock Holding Corporation

NasdaqGS:SRRK Stock Report

Mkt Cap: US$631.8m

SRRK Stock Overview

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.

SRRK fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

New

Notes are coming soon

Scholar Rock Holding Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Scholar Rock Holding
Historical stock prices
Current Share PriceUS$12.23
52 Week HighUS$21.17
52 Week LowUS$4.33
Beta0.64
1 Month Change27.66%
3 Month Change47.71%
1 Year Change-29.10%
3 Year Change-9.54%
5 Year Changen/a
Change since IPO-21.10%

Recent News & Updates

Scholar Rock: OLE Data In SMA Coupled With New CEO Make It A Buy

Oct 20

Recent updates

Scholar Rock: OLE Data In SMA Coupled With New CEO Make It A Buy

Oct 20

Jay Backstrom is the new CEO at Scholar Rock

Sep 20

Scholar Rock initiated at buy at Truist on platform for rare diseases and oncology

Jul 12

Brokers Are Upgrading Their Views On Scholar Rock Holding Corporation (NASDAQ:SRRK) With These New Forecasts

May 21
Brokers Are Upgrading Their Views On Scholar Rock Holding Corporation (NASDAQ:SRRK) With These New Forecasts

Broker Revenue Forecasts For Scholar Rock Holding Corporation (NASDAQ:SRRK) Are Surging Higher

Mar 08
Broker Revenue Forecasts For Scholar Rock Holding Corporation (NASDAQ:SRRK) Are Surging Higher

Scholar Rock Holding Corporation (NASDAQ:SRRK) Analysts Are More Bearish Than They Used To Be

May 15
Scholar Rock Holding Corporation (NASDAQ:SRRK) Analysts Are More Bearish Than They Used To Be

Is Scholar Rock Holding (NASDAQ:SRRK) Using Too Much Debt?

May 07
Is Scholar Rock Holding (NASDAQ:SRRK) Using Too Much Debt?

If You Had Bought Scholar Rock Holding (NASDAQ:SRRK) Stock A Year Ago, You Could Pocket A 283% Gain Today

Mar 01
If You Had Bought Scholar Rock Holding (NASDAQ:SRRK) Stock A Year Ago, You Could Pocket A 283% Gain Today

We Think Scholar Rock Holding (NASDAQ:SRRK) Can Afford To Drive Business Growth

Jan 05
We Think Scholar Rock Holding (NASDAQ:SRRK) Can Afford To Drive Business Growth

Scholar Rock EPS misses by $0.23, misses on revenue

Nov 09

Scholar Rock Is At Phase 2, $1 Billion Is Too Expensive

Nov 04

Scholar Rock prices ~$200M equity offering.

Oct 29

Shareholder Returns

SRRKUS BiotechsUS Market
7D-2.3%-0.3%1.7%
1Y-29.1%5.3%-9.1%

Return vs Industry: SRRK underperformed the US Biotechs industry which returned 3.9% over the past year.

Return vs Market: SRRK underperformed the US Market which returned -12.5% over the past year.

Price Volatility

Is SRRK's price volatile compared to industry and market?
SRRK volatility
SRRK Average Weekly Movement10.3%
Biotechs Industry Average Movement12.2%
Market Average Movement6.8%
10% most volatile stocks in US Market17.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: SRRK is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: SRRK's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2012145Jay Backstromhttps://scholarrock.com

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis.

Scholar Rock Holding Corporation Fundamentals Summary

How do Scholar Rock Holding's earnings and revenue compare to its market cap?
SRRK fundamental statistics
Market CapUS$631.84m
Earnings (TTM)-US$131.16m
Revenue (TTM)US$37.24m

17.0x

P/S Ratio

-4.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SRRK income statement (TTM)
RevenueUS$37.24m
Cost of RevenueUS$13.91m
Gross ProfitUS$23.33m
Other ExpensesUS$154.49m
Earnings-US$131.16m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.54
Gross Margin62.64%
Net Profit Margin-352.19%
Debt/Equity Ratio17.2%

How did SRRK perform over the long term?

See historical performance and comparison